Novel agents in front-line therapy for elderly patients: results of randomized studies.
| Author . | Palumbo37 . | Facon38 . | San Miguel43 . | Rajkumar24 . |
|---|---|---|---|---|
| *CR may be underestimated since bone marrow evaluation was not always performed. | ||||
| Abbreviations: MP, melphalan plus prednisone; MPT, MP plus thalidomide; MPV, MP plus bortezomib; RD, lenalidomide plus high-dose dexmethasone; Rd, lenalidomide plus low-dose dexamethsone; T, thalidomide; V, bortezomib; CR, complete response; VGPR, very good partial response; PR, partial response; PFS, progression-free survival | ||||
| Treatment | MPT vs MP | MPT vs MP | MPV vs MP | RD vs Rd |
| Duration of planned treatment | 6 mo + T until relapse in MPT arm | 18 mo | 54 wk | NA |
| Median duration of treatment | 8 m (T) | 11 m (T) | 46 w (V) | 4 m vs 6 m |
| Number of patients | 255 | 321 | 682 | 445 |
| Response rate, % | ||||
| CR | 15.5 vs 2.5 | 13 vs 2 | 35 vs 5 | 4 vs 2* |
| >VGPR | 36.5 vs 11 | 47 vs 7 | 45 vs 10 | 52 vs 42 |
| >PR | 76 vs 47.6 | 76 vs 35 | 82 vs 50 | 82 vs 71 |
| 2-year PFS, % | 54 vs 26 | 65 vs 35 | 45 vs 25 | 40 vs 40 |
| Thrombosis + embolism, % | 12 vs 2 | 12 vs 4 | 1 vs 1 | 25 vs 9 |
| Peripheral neuropathy, grade 3, % | 8 vs 1 | 6 vs 9 | 13 vs 0 | 2 vs 1 |
| Author . | Palumbo37 . | Facon38 . | San Miguel43 . | Rajkumar24 . |
|---|---|---|---|---|
| *CR may be underestimated since bone marrow evaluation was not always performed. | ||||
| Abbreviations: MP, melphalan plus prednisone; MPT, MP plus thalidomide; MPV, MP plus bortezomib; RD, lenalidomide plus high-dose dexmethasone; Rd, lenalidomide plus low-dose dexamethsone; T, thalidomide; V, bortezomib; CR, complete response; VGPR, very good partial response; PR, partial response; PFS, progression-free survival | ||||
| Treatment | MPT vs MP | MPT vs MP | MPV vs MP | RD vs Rd |
| Duration of planned treatment | 6 mo + T until relapse in MPT arm | 18 mo | 54 wk | NA |
| Median duration of treatment | 8 m (T) | 11 m (T) | 46 w (V) | 4 m vs 6 m |
| Number of patients | 255 | 321 | 682 | 445 |
| Response rate, % | ||||
| CR | 15.5 vs 2.5 | 13 vs 2 | 35 vs 5 | 4 vs 2* |
| >VGPR | 36.5 vs 11 | 47 vs 7 | 45 vs 10 | 52 vs 42 |
| >PR | 76 vs 47.6 | 76 vs 35 | 82 vs 50 | 82 vs 71 |
| 2-year PFS, % | 54 vs 26 | 65 vs 35 | 45 vs 25 | 40 vs 40 |
| Thrombosis + embolism, % | 12 vs 2 | 12 vs 4 | 1 vs 1 | 25 vs 9 |
| Peripheral neuropathy, grade 3, % | 8 vs 1 | 6 vs 9 | 13 vs 0 | 2 vs 1 |